Preparation of CHO cell-derived rhIFN-ω-Fc with improved pharmacokinetics

Antiviral Research

Volumn 89, Issue 3, 2011, Pages 199-203

  Li, Jianmin ^a   Li, Bing ^a   Zhang, Jun ^a   Hou, Lihua ^a   Yu, Changming ^a   Fu, Ling ^a   Song, Xiaohong ^a   Yu, Ting ^a   Zhang, Jinglong ^a   Ren, Jun ^a   Xu, Chun'e ^a   Chen, Wei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

CHO S; Pharmacokinetics; Physicochemical characterization; RhIFN ; RhIFN Fc

Indexed keywords

HYBRID PROTEIN; INTERFERON OMEGA FC FUSION PROTEIN; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CHINESE HAMSTER; CHO CELL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HALF LIFE TIME; HAMSTER; HEPATITIS C; HUMAN; HUMAN CELL; NONHUMAN; OVARY CELL; PHYSICAL CHEMISTRY; PLASMA HALF LIFE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RABBIT; SEQUENCE ANALYSIS; VESICULAR STOMATITIS VIRUS; YEAST;

ANIMALS; ANTIVIRAL AGENTS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CELL LINE; CHROMATOGRAPHY, AFFINITY; CRICETINAE; CRICETULUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN FC FRAGMENTS; INTERFERON TYPE I; RABBITS; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, PROTEIN; VESICULOVIRUS;

CRICETULUS GRISEUS; HEPATITIS C VIRUS; ORYCTOLAGUS CUNICULUS; VESICULAR STOMATITIS VIRUS;

EID: 79851514858     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.01.004     Document Type: Article

References (25)

1. Adolf G.R. Antigenic structure of human interferon omega 1 (interferon alpha II1): comparison with other human interferons. J. Gen. Virol. 1987, 68:1669-1676.
2. Adolf G.R., Maurer-Fogy I., Kalsner I., Cantell K. Purification and characterization of natural human interferon omega. 1. Two alternative cleavage sites for the signal peptidase. J. Biol. Chem. 1990, 265:9290-9295.
3. Berenguer J., González-García J., López-Aldeguer J., Von-Wichmann M.A., Quereda C., Hernando A., Sanz J., Tural C., Ortega E., Mallolas J., Santos I., Miralles P., Montes M.L., Bellón J.M., Esteban H. Pegylated interferon α2a plus ribavirin versus pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J. Antimicrob. Chemother. 2009, 63:1256-1263.
4. Briolant S., Garin D., Scaramozzino N., Jouan A., Crance J.M. In vitro inhibition of Chikungunya and Semliki Forest virus replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res. 2004, 61:111-117.
5. Buckwold V.E., Lang W., Scribner C., Blanchett D., Alessi T., Langecker P. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human ω-interferon produced from CHO-SS cells. Basic Clin. Pharmacol. Toxicol. 2006, 99:62-70.
6. Buckwold V.E., Wei J., Huang Z., Huang C., Nalca A., Wells J., Russell J., Collins B., Ptak R., Lang W., Scribner C., Blanchett D., Alessi T., Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res. 2007, 73:118-125.
7. Capon D.J., Shepard H.M., Goeddel D.V. Two distinct families of human and bovine interferon-α genes are coordinately expressed and encode functional polypeptides. Mol. Cell. Biol. 1985, 5:768-779.
8. Chang K.-O., George D.W. Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J. Virol. 2007, 81:12111-12118.
9. Crance J.M., Scaramozzino N., Jouan A., Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res. 2003, 58:73-79.
10. Dumont J.A., Low S.C., Peters R.T., Bitonti A.J. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006, 20:151-160.
11. Glue P., Fang J.W., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., Jacobs S. Pegylated interferon alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C intervention therapy group. Clin. Pharmacol. Ther. 2000, 68:556-567.
12. Hauptmann R., Swetly P. A novel class of human type I interferons. Nucleic Acids Res. 1985, 13:4739-4749.
13. Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol. 2009, 20:692-699.
14. Jazayeri J.A., Carroll G.J. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 2008, 22:11-26.
15. Jones T.D., Hanlon M., Smith B.J., Heise C.T., Nayee P.D., Sanders D.A., Hamilton A., Sweet C., Unitt E., Alexander G., Lo K.M., Gillies S.D., Carr F.J., Baker M.P. The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J. Interferon Cytokine Res. 2004, 24:560-572.
16. Julander J.G., Morrey J.D., Blatt L.M., Shafer K., Sidwell R.W. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res. 2007, 73:140-146.
17. Michaels A.J., Nelson D.R. New therapies in the management of hepatitis C virus. Curr. Opin. Gastroenterol. 2010, 26:196-201.
18. Okuse C., Rinaudo J.A., Farrar K., Wells F., Korba B.E. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res. 2005, 65:23-34.
19. Osborn B.L., Olsen H.S., Nardelli B., Murray J.H., Zhou J.X., Garcia A., Moody G., Zaritskaya L.S., Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 2002, 303:540-548.
20. Perry C.M., Jarvis B. Peginterferon-alpha-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs 2001, 61:2263-2288.
21. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines and their receptors. Immunol. Rev. 2004, 202:8-32.
22. Rustgi V.K. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr. Med. Res. Opin. 2009, 25:991-1002.
23. Schrieb K., Trummer E., Lattenmayer C., Weik R., Kunert R., Müller D., Katinger H., Vorauer-Uhl K. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expr. Purif. 2006, 49:265-275.
24. Stauber R.E., Stadlbauer V. Novel approaches for therapy of chronic hepatitis C. J. Clin. Virol. 2006, 36:87-94.
25. Zeuzem S., Yoshida E.M., Benhamou Y., Pianko S., Bain V.G., Shouval D., Flisiak R., Rehak V., Grigorescu M., Kaita K., Cronin P.W., Pulkstenis E., Subramanian G.M., McHutchison J.G. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008, 48:407-417.